Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech
(NASDAQ OMX NORDIC: ACTI) announced today that they have amended the
marketing and distribution agreement for oral laquinimod, an
investigational treatment for relapsing-remitting multiple sclerosis
(RRMS). Under the new agreement, Teva extended its marketing and
distribution rights to include the Nordic and Baltic regions, previously
held by Active Biotech. Active Biotech will receive a higher royalty
rate for sales in these territories compared to the royalty rate set
under the original licensing agreement signed in 2004 for sales in the
rest of the world.
“We are very excited about the market potential of laquinimod. We
believe that laqunimod can be a leading oral therapy for MS as it has
the potential to best combine the convenience of an oral formulation
with a favorable efficacy, safety and tolerability profile.”
“We are very excited about the market potential of laquinimod. We
believe that laqunimod can be a leading oral therapy for MS as it has
the potential to best combine the convenience of an oral formulation
with a favorable efficacy, safety and tolerability profile. ” said Moshe
Manor, Teva's Group VP, Global Branded Products. “Licensing a
promising new therapeutic option – as we did with laquinimod – is an
excellent example of how we plan to execute our branded strategy and
expand our innovative pipeline.”